These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37834095)

  • 21. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
    Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
    Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
    Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G
    Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
    Robak P; Robak T
    Drugs R D; 2019 Jun; 19(2):73-92. PubMed ID: 30993606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
    Elbæk CR; Petrosius V; Sørensen CS
    Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.
    Ba D; Li H; Liu R; Zhang P; Tang Y
    Apoptosis; 2023 Dec; 28(11-12):1534-1545. PubMed ID: 37243774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
    Summers RJ; Teachey DT
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
    Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
    Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe.
    Martin JC; Sims JR; Gupta A; Bakin AV; Ohm JE
    Cancer Res Commun; 2022 Jun; 2(6):471-482. PubMed ID: 36338546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
    Yue Y; Wang Y; He Y; Yang S; Chen Z; Wang Y; Xing S; Shen C; Amin HM; Wu D; Song YH
    PLoS One; 2014; 9(3):e90992. PubMed ID: 24608798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
    Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
    J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of bortezomib in the treatment of acute lymphoblastic leukemia.
    Zahid MF
    Future Oncol; 2016 Aug; 12(16):1861-4. PubMed ID: 27173950
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
    Citrin R; Foster JB; Teachey DT
    Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.